Review: taking Coumadin and Alli together


Summary

Drug interactions are reported among people who take Coumadin and Alli together. This review analyzes the effectiveness and drug interactions between Coumadin and Alli. It is created by eHealthMe based on reports of 295 people who take the same drugs from FDA and social media, and is updated regularly.

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Coumadin

Coumadin has active ingredients of warfarin sodium. It is often used in atrial fibrillation/flutter. (latest outcomes from Coumadin 101,806 users)

Alli

Alli has active ingredients of orlistat. It is often used in weight loss. (latest outcomes from Alli 19,208 users)

On Sep, 17, 2016

295 people who take Coumadin, Alli are studied.


Number of reports submitted per year:

Coumadin and Alli drug interactions.

Drug effectiveness over time:

Coumadin:
  • < 1 month: 0.0% - (0 of 0 people)
  • 1 - 6 months: 0.0% - (0 of 1 people)
  • 6 - 12 months: 0.0% - (0 of 0 people)
  • 1 - 2 years: 0.0% - (0 of 0 people)
  • 2 - 5 years: 0.0% - (0 of 0 people)
  • 5 - 10 years: 0.0% - (0 of 0 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 0.0% - (0 of 0 people)
Alli:
  • < 1 month: 0.0% - (0 of 1 people)
  • 1 - 6 months: 0.0% - (0 of 0 people)
  • 6 - 12 months: 0.0% - (0 of 0 people)
  • 1 - 2 years: 0.0% - (0 of 0 people)
  • 2 - 5 years: 0.0% - (0 of 0 people)
  • 5 - 10 years: 0.0% - (0 of 0 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 0.0% - (0 of 0 people)

Drug effectiveness by gender:

Coumadin:
  • female: 0.0% - (0 of 1 people)
  • male: 0.0% - (0 of 0 people)
Alli:
  • female: 0.0% - (0 of 1 people)
  • male: 0.0% - (0 of 0 people)

Drug effectiveness by age:

Coumadin:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 0 people)
  • 30-39: 0.0% - (0 of 0 people)
  • 40-49: 0.0% - (0 of 1 people)
  • 50-59: 0.0% - (0 of 0 people)
  • 60+: 0.0% - (0 of 0 people)
Alli:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 0 people)
  • 30-39: 0.0% - (0 of 0 people)
  • 40-49: 0.0% - (0 of 1 people)
  • 50-59: 0.0% - (0 of 0 people)
  • 60+: 0.0% - (0 of 0 people)

Most common drug interactions over time *:

< 1 month:
  • coagulopathy
  • international normalised ratio increased
  • chest pain
  • colitis
  • dehydration
  • diarrhoea
  • dizziness
  • haematochezia
  • pulmonary embolism
  • weight decreased
1 - 6 months:
  • osteoarthritis
  • pain
  • chest pain
  • dyspnoea
  • abdominal distension
  • anxiety
  • back pain
  • cough
  • ill-defined disorder
  • migraine
6 - 12 months:
  • international normalised ratio decreased
  • international normalised ratio increased
not specified:
  • international normalised ratio increased
  • atrial fibrillation
  • cardiac failure congestive
  • blood glucose increased
  • weight increased
  • fatigue
  • fluid retention
  • nausea
  • multiple injuries
  • cholecystitis acute

Most common drug interactions by gender *:

female:
  • international normalised ratio increased
  • atrial fibrillation
  • back pain
  • nausea
  • steatorrhoea
  • abdominal pain upper
  • cardiac failure congestive
  • chest pain
  • influenza like illness
  • vomiting
male:
  • international normalised ratio increased
  • cardiac failure congestive
  • weight increased
  • fluid retention
  • atrial fibrillation
  • cholecystitis acute
  • blood glucose increased
  • fatigue
  • aortic valve calcification
  • hypotension

Most common drug interactions by age *:

20-29:
  • bronchitis
  • cardiac failure congestive
  • cholecystitis
  • influenza like illness
  • insomnia
  • urinary tract infection
  • atrial fibrillation
  • intracardiac thrombus
  • mass
  • multi-organ failure
30-39:
  • headache
  • abdominal distension
  • anxiety
  • asthenia
  • back pain
  • dizziness
  • dyskinesia
  • dyspnoea
  • international normalised ratio decreased
  • irritability
40-49:
  • cholecystitis acute
  • aortic valve calcification
  • atrial fibrillation
  • cardiac failure
  • mitral valve incompetence
  • blood glucose increased
  • exercise tolerance decreased
  • hepatojugular reflux
  • brain natriuretic peptide increased
  • cardiomyopathy
50-59:
  • international normalised ratio increased
  • abdominal distension
  • abdominal pain upper
  • fluid retention
  • mouth ulceration
  • diarrhoea
  • difficulty in walking
  • face oedema
  • large intestinal haemorrhage
  • lower gastrointestinal haemorrhage
60+:
  • international normalised ratio increased
  • cardiac failure congestive
  • weight increased
  • fluid retention
  • urine output decreased
  • atrial fibrillation
  • steatorrhoea
  • pulmonary oedema
  • fatigue
  • lung disorder

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you take Coumadin and Alli?

Can you answer these questions?

More questions for: Coumadin, Alli

You may be interested in these reviews

More reviews for: Coumadin, Alli

On eHealthMe, Coumadin (warfarin sodium) is often used to treat atrial fibrillation/flutter. Alli (orlistat) is often used to treat weight loss. Find out below the conditions the drugs are used for and how effective they are.

What is the drug used for and how effecitve is it:


NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.